Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 vs Prevnar 13 in Healthy Infants
NCT02987972Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Primary completion
- Oct 2018
- Modality
- Split/Subunit Vaccines
- Countries
- 6
01
Overview
A Phase 2 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Mar 2017; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02987972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987972.